Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,819.62
(
0.54%
)
US TECH 100
24,343.00
(
0.41%
)
Dow Jones
48,173.86
(
0.55%
)
Brent Oil
94.05
(
-0.83%
)
Bitcoin
71,842.09
(
1.00%
)
News Focus
News Focus
Post# of 36
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Whalatane

Send PM Follow Ignore
Followers 142
Posts 23846
Boards Moderated 0
Alias Born 06/13/2011

Whalatane

Re: rosemountbomber post# 7

Tuesday, 05/07/2024 12:00:25 PM

Tuesday, May 07, 2024 12:00:25 PM

Post# of 36
RMB. I think we are due for data from the LYNX trial


, Edgewise Therapeutics expects to report 3-month data from the Phase 2 LYNX trial for EDG-5506 in the second quarter of 2024. The LYNX trial is a Phase 2 dose-ranging study to evaluate the safety and efficacy of EDG-5506 in patients with Duchenne muscular dystrophy (DMD).



New high today

Kiwi
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent EWTX News
More EWTX News